CZC-54252

Cat. No.: HY-B0792 Purity: 99.38%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

CZC-54252 is a potent and selective LRRK2 inhibitor with IC₅₀s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. CZC-54252 attenuates G2019S LRRK2-induced human neuronal injury with an EC₅₀ of ~1 nM. CZC-54252 has a neuroprotective activity.

For research use only. We do not sell to patients.

CZC-54252 Chemical Structure

CAS No. : 1191911-27-9

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 100	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 100	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 36	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 90	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 144	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 460	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 690	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of CZC-54252:

CZC-54252 hydrochloride Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC50: 1.28 nM (Wild-type LRRK2) and 1.85 nM (G2019S LRRK2)^[1]

In Vitro

CZC-54252 inhibits the activity of recombinant human wild-type LRRK2 with an IC₅₀ ranging from ～1 to ～5 nM. In addition, they are screened against a kinase panel of 185 kinases and exhibited good selectivity^[1].
G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 with an EC₅₀ of ~1 nM and fully reversed to wild-type levels by CZC-54252 at concentration of 1.6 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

504.99

Formula

C₂₂H₂₅ClN₆O₄S

CAS No.

1191911-27-9

Appearance

Solid

Color

White to off-white

SMILES

CS(=O)(NC1=CC=CC=C1NC2=NC(NC3=CC=C(N4CCOCC4)C=C3OC)=NC=C2Cl)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (198.02 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9802 mL	9.9012 mL	19.8024 mL
5 mM	0.3960 mL	1.9802 mL	3.9605 mL
10 mM	0.1980 mL	0.9901 mL	1.9802 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.38%

Select Batch:

Data Sheet (273 KB) SDS (393 KB)

COA (249 KB) LCMS (268 KB)

Handling Instructions (2659 KB)

References

[1]. Ramsden N, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011 Oct 21;6(10):1021-8. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9802 mL	9.9012 mL	19.8024 mL	49.5059 mL
	5 mM	0.3960 mL	1.9802 mL	3.9605 mL	9.9012 mL
	10 mM	0.1980 mL	0.9901 mL	1.9802 mL	4.9506 mL
	15 mM	0.1320 mL	0.6601 mL	1.3202 mL	3.3004 mL
	20 mM	0.0990 mL	0.4951 mL	0.9901 mL	2.4753 mL
	25 mM	0.0792 mL	0.3960 mL	0.7921 mL	1.9802 mL
	30 mM	0.0660 mL	0.3300 mL	0.6601 mL	1.6502 mL
	40 mM	0.0495 mL	0.2475 mL	0.4951 mL	1.2376 mL
	50 mM	0.0396 mL	0.1980 mL	0.3960 mL	0.9901 mL
	60 mM	0.0330 mL	0.1650 mL	0.3300 mL	0.8251 mL
	80 mM	0.0248 mL	0.1238 mL	0.2475 mL	0.6188 mL
	100 mM	0.0198 mL	0.0990 mL	0.1980 mL	0.4951 mL

CZC-54252 Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CZC-542521191911-27-9CZC54252CZC 54252LRRK2Leucine-rich repeat kinase 2neuroprotectiveneuronalinjuryLRRK2-G2019SInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks